<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) is a fatal, dominant <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorder</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> results from polyglutamine repeat expansion in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>-1 gene, conferring a toxic gain of function to the ataxin-3 protein </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we aimed at overexpressing ataxin-3 in the rat brain using lentiviral vectors (LV), to generate an in vivo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> genetic model and, to study the disorder in defined brain regions: substantia nigra, an area affected in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>, cortex and striatum, regions not previously reported to be affected in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>LV encoding mutant or <z:mp ids='MP_0002169'>wild-type</z:mp> human ataxin-3 was injected in the brain of adult rats and the animals were tested for behavioral deficits and neuropathological abnormalities </plain></SENT>
<SENT sid="4" pm="."><plain>Striatal pathology was confirmed in transgenic mice and human tissue </plain></SENT>
<SENT sid="5" pm="."><plain>In substantia nigra, unilateral overexpression of mutant ataxin-3 led to: <z:chebi fb="1" ids="48538">apomorphine</z:chebi>-induced turning behavior; formation of ubiquitinated ataxin-3 aggregates; alpha-synuclein immunoreactivity; and loss of dopaminergic markers (TH and VMAT2) </plain></SENT>
<SENT sid="6" pm="."><plain>No neuropathological changes were observed upon <z:mp ids='MP_0002169'>wild-type</z:mp> ataxin-3 overexpression </plain></SENT>
<SENT sid="7" pm="."><plain>Mutant ataxin-3 expression in striatum and cortex, resulted in accumulation of misfolded ataxin-3, and within striatum, loss of neuronal markers </plain></SENT>
<SENT sid="8" pm="."><plain>Striatal pathology was confirmed by observation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> transgenic mice of ataxin-3 aggregates and substantial reduction of DARPP-32 immunoreactivity and, in human striata, by ataxin-3 inclusions, immunoreactive for ubiquitin and alpha-synuclein </plain></SENT>
<SENT sid="9" pm="."><plain>This study demonstrates the use of LV encoding mutant ataxin-3 to produce a model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> and brings evidence of striatal pathology, suggesting that this region may contribute to <z:hpo ids='HP_0001332'>dystonia</z:hpo> and <z:hpo ids='HP_0002072'>chorea</z:hpo> observed in some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients and may represent a target for therapies </plain></SENT>
</text></document>